TP53 is a tumor suppressor gene, known as "the guardian of the genome", and mutations in this gene are one of the most frequent mutations in BC, being identified in almost 30% of cases [11]. The literature shows contradictory results regarding the clinical relevance of its mutated state, since it has been associated with negative, positive and neutral results, so it is still a subject of debate [11]. Therefore, it does not seem that the aggressive course observed in our patients can be explained solely by an alteration in this gene. This evidence concerns the gene TP53 and breast cancer.